Home

PQ Bypass has announced that they received breakthrough device designation from the US Food and Drug Administration (FDA) for the Detour system. The Detour system is the world’s first fully-percutaneous femoral-popliteal bypass device intended to treat extremely long, complex blockages in the superficial femoral artery (SFA).

Physician access to this device can now be expedited as a result of this designation by the FDA breakthrough device programme, which is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Under the programme, the FDA will provide PQ Bypass with priority review and interactive communication regarding device development and clinical trial protocols, during the premarket review process.

“As this is a first-of-its-kind device, we are pleased to have the FDA recognise the novelty and potential of our therapeutic approach in treating severe SFA,” said Heather Simonsen, general manager at PQ Bypass. “We appreciate their collaborative review of our breakthrough device designation request and look forward to a continued productive relationship as we continue towards PMA submission.”

The Detour system is designed to treat patients who are unable to carry out activities of daily living and are unable to enjoy the liberties of free mobility as a result of their advanced symptomology, severe lesion morphology, and multiple comorbidities.

Once peripheral arterial disease (PAD) progresses to debilitating claudication or tissue loss, revascularisation becomes imperative to mitigate the ongoing deterioration and to prevent amputation. Left untreated, these patients are at greater risk for further functional deterioration, major adverse limb events, and mortality.

“This designation is a major milestone for PQ Bypass, and we expect this technology to change the paradigm for complex SFA treatment in the way EVAR [endovascular aneurysm repair] and TAVR [transcatheter aortic valve replacement] changed the paradigm for aortic repair,” said Rich Ferrari, chairman and CEO of PQ Bypass.

“We are nearing enrolment completion in our DETOUR2 and TORUS2 IDE [investigational device exemption] studies, and had new positive data on our technology published in the Journal of Vascular Surgery, making 2020 a momentous year for the company. This is an exciting time for all of us at PQ, with this important designation a credit to such a talented group. We are honoured and proud to be part of this important journey to develop a first-line therapy in the treatment of advanced PAD.”

Source VascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: PQ Bypass receives FDA breakthrough device designation for its Detour system

Chia sẽ qua google bài: PQ Bypass receives FDA breakthrough device designation for its Detour system

Chia sẽ qua twitter bài: PQ Bypass receives FDA breakthrough device designation for its Detour system

Chia sẽ qua MySpace bài: PQ Bypass receives FDA breakthrough device designation for its Detour system

Chia sẽ qua LinkedIn bài: PQ Bypass receives FDA breakthrough device designation for its Detour system

Chia sẽ qua stumbleupon bài: PQ Bypass receives FDA breakthrough device designation for its Detour system

Chia sẽ qua icio bài: PQ Bypass receives FDA breakthrough device designation for its Detour system

Chia sẽ qua digg bài: PQ Bypass receives FDA breakthrough device designation for its Detour system

Chia sẽ qua yahoo bài: PQ Bypass receives FDA breakthrough device designation for its Detour system

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.